ASH Earnings Prediction
The chart below shows how ASH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ASH sees a -0.52% change in stock price 10 days leading up to the earnings, and a -0.47% change 10 days following the report. On the earnings day itself, the stock moves by +0.56%. This data can give you a slight idea of what to expect for the next quarter's release.
ASH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
473.00M
-9.90%
-8.51%
Gross Margin
20.72%
-23.40%
2.02%
Operating Margin
3.38%
-63.77%
191.38%
Net Margin
5.92%
-26.00%
-481.94%
EPS
0.51
-30.14%
-737.50%
No Data Available
ASH Earnings Analysis
Ashland Inc Corporation (ASH.N) Earnings Conference Call
Positive
EBITDA Margin Improvement: Adjusted EBITDA margin improved by 30 basis points year over year to 15.1%, despite challenges, indicating effective cost management and operational efficiency.
Personal Care EBITDA Growth: Personal Care segment achieved its fourth consecutive quarter of over 25% year-over-year EBITDA growth, driven by strong demand in skincare and hair care markets.
Gross Profit Margin Increase: Gross profit margin increased by 290 basis points to 28.1% in Q1, primarily due to production volume recovery and successful portfolio optimization actions.
Cost-Saving Initiatives: The company has successfully identified $21 million in cost-saving opportunities as part of a $30 million restructuring initiative, demonstrating proactive cost management efforts.
Strong Cash Position: Ashland's cash position remains strong with $219 million on hand and $815 million in total available liquidity, supporting ongoing investments and shareholder returns.
Negative
Q1 Sales Decline: Q1 sales were $405 million, down 14% from the prior year, primarily due to portfolio improvement actions, including a new pharmaceutical divestiture.
EBITDA Decline Analysis: Adjusted EBITDA decreased to $61 million, down 13% year over year, driven by lost gross profit from the sale of nutraceuticals and stranded costs from portfolio optimization actions.
Life Sciences Sales Decline: Life Sciences sales declined 33% to $134 million, with organic sales down 12% year over year, primarily due to softer pharma market conditions and customer inventory control measures.
Adjusted EPS Decline: Adjusted EPS was $0.28, down 38% from the prior year, reflecting the impact of divestitures and lower sales volumes.
Pricing Decline Analysis: Overall pricing was down 2% year over year, primarily in the Intermediates and Life Sciences segments, indicating a challenging pricing environment.
ASH FAQs
How does ASH typically perform around its earnings report dates?
Is Ashland Inc (ASH) Q1 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ASH Earning Call Sentiment
Earnings call transcript: Ashland Q1 2024 misses revenue forecast, shares fall
ASH.N
0.94%Positive
The earnings call reveals several challenges: declining sales and EBITDA, stranded costs, and economic uncertainties, particularly in Europe and China. While there are positive aspects like share repurchases and dividend growth, concerns about trade policies, currency impacts, and lack of clear guidance contribute to a negative sentiment. The market cap suggests a moderate reaction, leading to a prediction of a negative stock price movement.
